- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02184442
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B (PARTNERII B)
The PARTNER II Trial "Placement of AoRTic TraNscathetER" Valves Trial" (US) [PII B] for Inoperable Patients
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Cohort B was a 1:1 randomized, controlled study independently powered to compare transcatheter heart valve therapy with the first generation (SAPIEN™ THV) system to transcatheter heart valve therapy with the second generation (SAPIEN XT THV) system in patients who could not undergo surgery (inoperable).
Patients in the control arm of Cohort B received an Edwards SAPIEN THV with the associated delivery system while patients in the treatment arm of Cohort B received an Edwards SAPIEN XT THV with the associated delivery system.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72211
- Arkansas Heart Hospital/Clinic
-
-
California
-
La Jolla, California, Stati Uniti, 92037
- Scripps Green Hospital
-
La Jolla, California, Stati Uniti, 92037
- Scripps Memorial Hospital
-
Los Angeles, California, Stati Uniti, 90048
- Cedars-Sinai Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Mercy General Hospital
-
Stanford, California, Stati Uniti, 94305
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20010
- Washington Hospital Center (WHC)
-
-
Florida
-
Clearwater, Florida, Stati Uniti, 33756
- Morton Plant Hospital
-
Gainesville, Florida, Stati Uniti, 32610
- University of Florida, Gainesville
-
Miami, Florida, Stati Uniti, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Rush University Medical Center
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern Hospital
-
Springfield, Illinois, Stati Uniti, 62701
- Prairie Education And Research Cooperative
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University Health-Methodist Hospital
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- The University of Iowa
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40202
- University of Louisville - Jewish Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Royal Oak, Michigan, Stati Uniti, 48073
- William Beaumont Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Hospital of Kansas City Mid America
-
Saint Louis, Missouri, Stati Uniti, 63110
- Washington University - Barnes Jewish Hospital
-
-
Nebraska
-
Lincoln, Nebraska, Stati Uniti, 68526
- Nebraska Heart Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07112
- Newark Beth Israel
-
-
New York
-
Manhasset, New York, Stati Uniti, 11030
- North Shore University Hospital, NY
-
Mineola, New York, Stati Uniti, 11501
- Winthrop University Hospital
-
New York, New York, Stati Uniti, 10032
- Columbia University Medical Center
-
New York, New York, Stati Uniti, 10021
- Cornell University
-
-
North Carolina
-
Charleston, North Carolina, Stati Uniti, 29425
- Medical University of South Carolina Charleston
-
Greenville, North Carolina, Stati Uniti, 27834
- East Carolina Heart Institute at East Carolina University
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- The Christ Hospital, Cincinnati
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73135
- Oklahoma Heart Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania Hospital
-
York, Pennsylvania, Stati Uniti, 17403
- York Hospital
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38120
- Baptist Memorial Hospital
-
-
Texas
-
Austin, Texas, Stati Uniti, 78756
- Austin Heart, PLLC
-
Dallas, Texas, Stati Uniti, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, Stati Uniti, 75093
- The Heart Hospital Baylor Plano
-
Houston, Texas, Stati Uniti, 77030
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Stati Uniti, 78229-3900
- University of Texas Health Science Center at San Antonio (UTHSCSA)
-
-
Utah
-
Murray, Utah, Stati Uniti, 84157
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22904
- University of Virginia
-
Norfolk, Virginia, Stati Uniti, 23507
- Sentara Norfolk General Hospital
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin - Madison
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
- Patient was symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
- The probability of death or serious, irreversible morbidity is greater than or equal to 50%.
- The heart team agreed (and verified in the case review process) that valve implantation would likely benefit the patient.
- The study patient or the study patient's legal representative was informed of the nature of the study, agreed to its provisions and had provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- The study patient agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone follow-up.
Exclusion Criteria
- Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
- Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- It is known that the patient is currently enrolled in the PARTNER I Trial or was withdrawn from the PARTNER I Trial prior to endpoint analysis.
- Active bacterial endocarditis within 6 months (180 days) of procedure.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: TAVR - SAPIEN XT
TAVR (transaortic valve replacement) with SAPIEN XT
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
|
Comparatore attivo: TAVR - SAPIEN
TAVR (transaortic valve replacement) with SAPIEN is the control arm
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization
Lasso di tempo: 1 Year
|
All-Cause Mortality and/or Major Stroke and/or Rehospitalization at 1 Year
|
1 Year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
NYHA Classification - Change From Baseline
Lasso di tempo: Baseline and 1 Year
|
New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity.
The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.
|
Baseline and 1 Year
|
|
Total Aortic Regurgitation - Change From Baseline
Lasso di tempo: 1 Year
|
Total aortic regurgitation was assessed by the core lab as 'Grade 0' = None, 'Grade 1+' = Trace, 'Grade 2+' = Mild, 'Grade 3+' = Moderate, and 'Grade 4+' = Severe. Total regurgitation at one year was analyzed in the valve implant population. |
1 Year
|
|
Effective Orifice Area - Change From Baseline
Lasso di tempo: 1 Year
|
1 Year
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Martin B Leon, MD, Columbia University
Pubblicazioni e link utili
Pubblicazioni generali
- Chen S, Redfors B, O'Neill BP, Clavel MA, Pibarot P, Elmariah S, Nazif T, Crowley A, Ben-Yehuda O, Finn MT, Alu MC, Vahl TP, Kodali S, Leon MB, Lindman BR. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. Eur Heart J. 2020 Feb 21;41(8):958-969. doi: 10.1093/eurheartj/ehz892.
- Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, Makkar RR, Pibarot P, Webb JG, Leipsic J, Alu MC, Crowley A, Hahn RT, Kapadia SR, Tuzcu EM, Svensson L, Cremer PC, Jaber WA. Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials. Circulation. 2019 Dec 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. Epub 2019 Nov 6.
- Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, Hahn RT, Kodali S, Thourani VH, Douglas PS, Alu MC, Fearon WF, Passeri J, Malaisrie SC, Crowley A, McAndrew T, Genereux P, Ben-Yehuda O, Leon MB, Burkhoff D. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials. Circ Heart Fail. 2019 Aug;12(8):e005809. doi: 10.1161/CIRCHEARTFAILURE.118.005809. Epub 2019 Aug 1.
- Genereux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, Kapadia S, Thourani VH, Mack MJ, Nazif TM, Lindman BR, Babaliaros V, Vincent F, Russo M, McCabe JM, Gillam LD, Alu MC, Hahn RT, Webb JG, Leon MB, Cohen DJ. Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement. J Am Coll Cardiol. 2022 Aug 23;80(8):783-800. doi: 10.1016/j.jacc.2022.05.006. Epub 2022 May 17.
- Shahim B, Redfors B, Lindman BR, Chen S, Dahlen T, Nazif T, Kapadia S, Gertz ZM, Crowley AC, Li D, Thourani VH, Kodali SK, Zajarias A, Babaliaros VC, Guyton RA, Elmariah S, Herrmann HC, Cohen DJ, Mack MJ, Smith CR, Leon MB, George I. Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Heart Assoc. 2022 Jun 7;11(11):e024091. doi: 10.1161/JAHA.121.024091. Epub 2022 Jun 3.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2010-12-PIIB
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su TAVR Implantation with SAPIEN XT
-
Claret MedicalCompletatoStenosi della valvola aortica nativa calcificata sintomatica graveStati Uniti, Germania
-
Edwards LifesciencesCompletatoStenosi aortica grave sintomaticaStati Uniti, Canada
-
Institut für Pharmakologie und Präventive MedizinEstimate, GmbHCompletatoMalfunzionamento della valvola polmonareBelgio, Canada, Svizzera
-
Edwards LifesciencesCompletatoStenosi della valvola aorticaGiappone
-
Edwards LifesciencesCompletatoMalattie cardiache | Malattia cardiovascolare | Anomalie congenite | Difetti cardiaci, congeniti | Insufficienza della valvola polmonare | Stenosi della valvola polmonareStati Uniti
-
LMU KlinikumCompletatoStenosi della valvola aorticaGermania
-
Edwards LifesciencesCompletato
-
Edwards LifesciencesCompletatoStenosi della valvola aorticaRegno Unito, Germania, Francia, Austria
-
University of PadovaEdwards Lifesciences; Azienda Ospedaliera di Padova; Ospedale San Bortolo di VicenzaSospesoStenosi della valvola aorticaItalia
-
Edwards LifesciencesCompletatoStenosi aortica grave sintomaticaStati Uniti, Canada